PGGM Investments Cuts Holdings in Hologic, Inc. (NASDAQ:HOLX)

PGGM Investments lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,577 shares of the medical equipment provider’s stock after selling 781 shares during the period. PGGM Investments’ holdings in Hologic were worth $7,329,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new position in Hologic in the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC purchased a new position in Hologic in the 3rd quarter worth approximately $29,000. NBC Securities Inc. purchased a new position in Hologic in the 3rd quarter worth approximately $33,000. Deseret Mutual Benefit Administrators grew its stake in Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its stake in Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 227 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Evercore ISI upped their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, Raymond James upped their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Trading Up 0.4 %

NASDAQ:HOLX traded up $0.27 during midday trading on Friday, reaching $75.98. 919,462 shares of the stock traded hands, compared to its average volume of 1,442,585. The company has a fifty day moving average of $76.03 and a 200 day moving average of $72.79. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The stock has a market capitalization of $17.83 billion, a P/E ratio of 36.01, a PEG ratio of 2.57 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same period in the prior year, the business posted $1.07 EPS. The firm’s revenue was down 5.7% compared to the same quarter last year. On average, research analysts predict that Hologic, Inc. will post 4.01 EPS for the current year.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.